Keyword search (4,163 papers available)

"Leyton M" Authored Publications:

Title Authors PubMed ID
1 Decriminalization or more treatment? Comparing 2 approaches to the drug overdose crisis Caswell C; Krausz RM; Leyton M; 40541419
CSBN
2 A multimodal neuroimaging study of youth at risk for substance use disorders: Functional magnetic resonance imaging and [18F]fallypride positron emission tomography Nikolic M; Cox SML; Jaworska N; Castellanos-Ryan N; Dagher A; Vitaro F; Brendgen M; Parent S; Boivin M; Côté S; Tremblay RE; Séguin JR; Leyton M; 39725679
CSBN
3 Ending the overdose epidemic by ending the war on drug users: Can this work? Leyton M; Krausz RM; 38383036
CSBN
4 Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation Scala SG; Kang MS; Cox SML; Rosa-Neto P; Massarweh G; Leyton M; 38221806
CSBN
5 Learning from opioid withdrawal: Effects on striatal dopamine (Commentary on Ahn et al., 2023) Leyton M; Nikolic M; 38129315
CSBN
6 Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; 38006502
PERFORM
7 Cocaine cue-induced mesocorticolimbic activation in cocaine users: Effects of personality traits, lifetime drug use, and acute stimulant ingestion D' Amour-Horvat V; Cox SML; Dagher A; Kolivakis T; Jaworska N; Leyton M; 34463411
CSBN
8 Why did the kitten cross the road? A meditation on positive versus negative reinforcement in addiction. Leyton M 33497168
CSBN
9 Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C 32559027
CSBN
10 mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use. Cox SML, Tippler M, Jaworska N, Smart K, Castellanos-Ryan N, Durand F, Allard D, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté S, Tremblay RE, Séguin JR, Leyton M 32413893
CSBN
11 Extra-striatal D2/3 receptor availability in youth at risk for addiction. Jaworska N, Cox SML, Tippler M, Castellanos-Ryan N, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté SM, Tremblay RE, Séguin JR, Leyton M 32259831
CSBN
12 Cannabis legalization: Did we make a mistake? Update 2019 Leyton M 31452361
PSYCHOLOGY
13 Legalizing marijuana. Leyton M 26898727
CSBN
14 Cocaine cue-induced dopamine release in the human prefrontal cortex. Milella MS, Fotros A, Gravel P, Casey KF, Larcher K, Verhaeghe JA, Cox SM, Reader AJ, Dagher A, Benkelfat C, Leyton M 26900792
CSBN
15 Dopamine and light: effects on facial emotion recognition. Cawley E, Tippler M, Coupland NJ, Benkelfat C, Boivin DB, Aan Het Rot M, Leyton M 28633582
CSBN
16 Are people with psychiatric disorders violent? Leyton M 29688170
CSBN
17 Are people with psychiatric disorders violent? Leyton M 29947604
CSBN
18 Neuroimaging tests for clinical psychiatry: Are we there yet? Leyton M, Kennedy SH 28639935
IMAGING
19 Dopamine cross-sensitization between psychostimulant drugs and stress in healthy male volunteers. Booij L, Welfeld K, Leyton M, Dagher A, Boileau I, Sibon I, Baker GB, Diksic M, Soucy JP, Pruessner JC, Cawley-Fiset E, Casey KF, Benkelfat C 26905412
PSYCHOLOGY
20 Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans. Smart K, Cox SML, Kostikov A, Shalai A, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M 30607444
CSBN
21 Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors. Smart K, Cox SML, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M 30627817
CSBN
22 Posterior dopamine D2/3 receptors and brain network functional connectivity. Nagano-Saito A, Lissemore JI, Gravel P, Leyton M, Carbonell F, Benkelfat C 28700819
PERFORM

 

Title:mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use.
Authors:Cox SML,  Tippler M,  Jaworska N,  Smart K,  Castellanos-Ryan N,  Durand F,  Allard D,  Benkelfat C,  Parent S,  Dagher A,  Vitaro F,  Boivin M,  Pihl RO,  Côté S,  Tremblay RE,  Séguin JR,  Leyton M
Link:https://www.ncbi.nlm.nih.gov/pubmed/32413893?dopt=Abstract
DOI:10.1038/s41386-020-0708-x
Publication:Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Keywords:
PMID:32413893 Category:Neuropsychopharmacology Date Added:2020-05-16
Dept Affiliation: CSBN
1 Department of Psychiatry, McGill University, Montreal, QC, Canada.
2 Department of Neurology & Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
3 Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
4 Institute of Mental Health Research, Affiliated with the University of Ottawa, Ottawa, ON, Canada.
5 Yale PET Center, Yale University, New Haven, CT, USA.
6 School of Psychoeducation, Université de Montréal, Montreal, QC, Canada.
7 CHU Ste-Justine Research Center, Montreal, QC, Canada.
8 Department of Psychology, Université Laval, Quebec, QC, Canada.
9 Department of Psychology, McGill University, Montreal, QC, Canada.
10 Department of Social and Preventative Medicine, Université de Montréal, Montreal, QC, Canada.
11 Department of Pediatrics and Psychology, Université de Montréal, Montreal, QC, Canada.
12 School of Public Health, University College Dublin, Belfield, Dublin, Ireland.
13 Department of Psychiatry and Addictology, Université de Montréal, Montreal, QC, Canada.
14 Department of Psychiatry, McGill University, Montreal, QC, Canada. marco.leyton@mcgill.ca.
15 Department of Neurology & Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada. marco.leyton@mcgill.ca.
16 Department of Psychology, McGill University, Montreal, QC, Canada. marco.leyton@mcgill.ca.
17 Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC, Canada. marco.leyton@mcgill.ca.

Description:

mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use.

Neuropsychopharmacology. 2020 May 15;:

Authors: Cox SML, Tippler M, Jaworska N, Smart K, Castellanos-Ryan N, Durand F, Allard D, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté S, Tremblay RE, Séguin JR, Leyton M

Abstract

The excitatory neurotransmitter glutamate has been implicated in experience-dependent neuroplasticity and drug-seeking behaviors. Type 5 metabotropic glutamate (mGlu5) receptors might be particularly important. They are critically involved in synaptic plasticity and their availability has been reported to be lower in people with alcohol, tobacco, and cocaine use disorders. Since these reductions could reflect effects of drug use or pre-existing traits, we used positron emission tomography to measure mGlu5 receptor availability in young adults at elevated risk for addictions. Fifty-nine participants (age 18.5±0.6) were recruited from a longitudinal study that has followed them since birth. Based on externalizing traits that predict future substance use problems, half were at low risk, half were at high risk. Cannabis use histories varied markedly and participants were divided into three subgroups: zero, low, and high use. Compared to low risk volunteers, those at elevated risk had lower [11C]ABP688 binding potential (BPND) values in the striatum, amygdala, insula, and orbitofrontal cortex (OFC). Cannabis use by risk group interactions were observed in the striatum and OFC. In these regions, low [11C]ABP688 BPND values were only seen in the high risk group that used high quantities of cannabis. When these high risk, high cannabis use individuals were compared to all other participants, [11C]ABP688 BPND values were lower in the striatum, OFC, and insula. Together, the study provides evidence that mGlu5 receptor availability is low in youth at elevated risk for addictions, particularly those who frequently use cannabis.

PMID: 32413893 [PubMed - as supplied by publisher]




BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University